Successful Treatment of Nail Psoriasis with Topical Roflumilast: A Case Report

Overview

Journal SAGE Open Med Case Rep

Publisher Sage Publications

Specialty General Medicine

Date 2024 Nov 1

PMID 39483845

Authors

Leah A Johnston

Susan M Poelman

Affiliations

Soon will be listed here.

Abstract

Nail psoriasis occurs in approximately half of all cases of plaque psoriasis and manifests with onychodystrophy, which includes morphological features of onycholysis, subungual hyperkeratosis, oil drop sign, pitting, splinter hemorrhages, leukonychia, and crumbling of the nails. Nail psoriasis can have a significant adverse impact on quality of life. However, nail psoriasis is often refractory to both local and systemic therapies, making it challenging to treat. Topical and oral phosphodiesterase-4 inhibitors have been successfully used to treat multiple different subtypes of psoriasis. Topical roflumilast, a phosphodiesterase-4 inhibitor cream, has recently received United States Food and Drug Administration and Health Canada approval for the treatment of plaque psoriasis. In this case report, a 25-year-old female with a 20-year history of nail psoriasis achieved complete resolution of her onychodystrophy after 5 months of daily application of topical roflumilast, without experiencing any side effects. This case report suggests that topical roflumilast may be a useful and well-tolerated therapy for psoriatic nails.

References

Kreutz T, de Matos S, Koester L . Recent Patents on Permeation Enhancers for Drug Delivery Through Nails. Recent Pat Drug Deliv Formul. 2019; 13(3):203-218. PMC: 7011684. DOI: 10.2174/1872211313666191030155837. View

Schons K, Beber A, Beck M, Monticielo O . Nail involvement in adult patients with plaque-type psoriasis: prevalence and clinical features. An Bras Dermatol. 2015; 90(3):314-9. PMC: 4516108. DOI: 10.1590/abd1806-4841.20153736. View

Thurston Jr A, Osborne D, Snyder S, Higham R, Burnett P, Berk D . Pharmacokinetics of Roflumilast Cream in Chronic Plaque Psoriasis: Data from Phase I to Phase III Studies. Am J Clin Dermatol. 2022; 24(2):315-324. PMC: 9968262. DOI: 10.1007/s40257-022-00741-9. View

OToole A, Gooderham M . Topical Roflumilast for Plaque Psoriasis. Skin Therapy Lett. 2023; 28(5):1-4. View

Lanna C, Cesaroni G, Mazzilli S, Vollono L, Gaziano R, Marino D . Apremilast as a target therapy for nail psoriasis: a real-life observational study proving its efficacy in restoring the nail unit. J Dermatolog Treat. 2020; 33(2):1097-1101. DOI: 10.1080/09546634.2020.1801976. View

Rashmi R, Rao K, Basavaraj K . A comprehensive review of biomarkers in psoriasis. Clin Exp Dermatol. 2009; 34(6):658-63. DOI: 10.1111/j.1365-2230.2009.03410.x. View

Goldminz A, Au S, Kim N, Gottlieb A, Lizzul P . NF-κB: an essential transcription factor in psoriasis. J Dermatol Sci. 2012; 69(2):89-94. DOI: 10.1016/j.jdermsci.2012.11.002. View

Saulite I, Pilmane M, Guenova E, kisis J . Expression of inflammatory cytokines in psoriatic nails. J Eur Acad Dermatol Venereol. 2016; 31(4):e210-e212. DOI: 10.1111/jdv.13970. View

Ventura A, Mazzeo M, Gaziano R, Galluzzo M, Bianchi L, Campione E . New insight into the pathogenesis of nail psoriasis and overview of treatment strategies. Drug Des Devel Ther. 2017; 11:2527-2535. PMC: 5587086. DOI: 10.2147/DDDT.S136986. View

10.

Smirnova L, Vertieva E, Olisova O, Anpilogova E . Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau. Biologics. 2019; 13:83-87. PMC: 6535620. DOI: 10.2147/BTT.S199100. View

11.

Cutrin-Gomez E, Anguiano-Igea S, Begona Delgado-Charro M, Gomez-Amoza J, Otero-Espinar F . Effect of Penetration Enhancers on Drug Nail Permeability from Cyclodextrin/Poloxamer-Soluble Polypseudorotaxane-Based Nail Lacquers. Pharmaceutics. 2018; 10(4). PMC: 6321522. DOI: 10.3390/pharmaceutics10040273. View

12.

Hwang J, Grover C, Iorizzo M, Lebwohl M, Piraccini B, Rigopoulos D . Nail psoriasis and nail lichen planus: Updates on diagnosis and management. J Am Acad Dermatol. 2023; 90(3):585-596. DOI: 10.1016/j.jaad.2023.11.024. View

13.

Kushwaha A, Repka M, Murthy S . A Novel Apremilast Nail Lacquer Formulation for the Treatment of Nail Psoriasis. AAPS PharmSciTech. 2017; 18(8):2949-2956. DOI: 10.1208/s12249-017-0776-3. View

14.

Eder L, Widdifield J, Rosen C, Cook R, Lee K, Alhusayen R . Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study. Arthritis Care Res (Hoboken). 2018; 71(8):1084-1091. DOI: 10.1002/acr.23743. View

15.

Cornaghi L, Gagliano N, Preis F, Prignano F, Donetti E . Inside-out and outside-in organotypic normal human skin culture: JAK-STAT pathway is activated after pro-inflammatory psoriatic cytokine exposure. Tissue Cell. 2021; 74:101675. DOI: 10.1016/j.tice.2021.101675. View